Evidence map›Paper›PMID 25567050›Full record

ArticleJournal of the American Heart Association2015

Self-controlled case-series study to verify the effect of adherence to Beta-blockers in secondary prevention of myocardial infarction.

Stefano Di Bartolomeo, Massimiliano Marino, Paolo Guastaroba, Francesca Valent, Rossana De Palma

Abstract readComparative Study
In one paragraph

Article in Journal of the American Heart Association, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. A Query Engine for Self-controlled Case Series, with an application to COVID-19 EHR data.AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science · 2023
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Stefano Di BartolomeoRegional Agency for Health and Social Care of Emilia-Romagna/Azienda Ospedaliero-Universitaria di Udine, Bologna/Udine, Italy (S.D.B., M.M., P.G., R.D.P.).
Massimiliano MarinoRegional Agency for Health and Social Care of Emilia-Romagna/Azienda Ospedaliero-Universitaria di Udine, Bologna/Udine, Italy (S.D.B., M.M., P.G., R.D.P.).
Paolo GuastarobaRegional Agency for Health and Social Care of Emilia-Romagna/Azienda Ospedaliero-Universitaria di Udine, Bologna/Udine, Italy (S.D.B., M.M., P.G., R.D.P.).
Francesca ValentServizio di Epidemiologia, Direzione Centrale Salute, Integrazione Sociosanitaria e Politiche Sociali, Regione Autonoma Friuli Venezia Giulia, Udine, Italy (F.V.).
Rossana De PalmaRegional Agency for Health and Social Care of Emilia-Romagna/Azienda Ospedaliero-Universitaria di Udine, Bologna/Udine, Italy (S.D.B., M.M., P.G., R.D.P.).

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBeta-blockers (BB) are recommended in secondary prevention of acute myocardial infarction (AMI), but adherence to prescription medication is a recognized problem. Most literature on the consequences of poor adherence to prescribed BB is limited by the possibility of "healthy adherer bias" and better-designed studies have been advocated. METHODS AND

resultsWe investigated the association between adherence to BB prescription and risk of subsequent AMIs using the self-controlled case series design, which allows improved control of interpersonal confounding, being based on intrapersonal comparisons. From all the 30 089 patients hospitalized for AMI in the years 2009-2011 in an Italian region we selected those that suffered subsequent AMIs at days 31 to 365 from discharge (1328), and then the 1207 that had at least one BB prescription collected at any of the regional pharmacies. Using information on prescriptions, each individual's observation time was then divided into periods exposed or unexposed to BB and the relative AMI incidence rate ratios (IRR) of BB exposure were estimated by conditional Poisson regression. The IRR (rate of recurrent AMI in exposed versus unexposed periods) was 0.79 (95% CI 0.69 to 0.90, P=0.001). Various sensitivity analyses confirmed the robustness to possible failure of assumptions, ie, considering only first recurrences (IRR 0.76, 95% CI 0.66 to 0.88, P<0.001), excluding cardiovascular fatalities (IRR 0.76, 95% CI 0.65 to 0.89, P<0.001), and excluding individuals with long hospital admissions (IRR 0.60, 95% CI 0.43 to 0.83, P=0.002).

conclusionsAdherence to recommended BB therapy was associated with a 20% reduction of recurrent AMIs, consistently with previous research, but with decreased concerns about healthy-adherer bias.

Indexed as

Drug MonitoringRegistriesAdrenergic beta-AntagonistsAgedCase-Control StudiesContinuity of Patient CareFemaleFollow-Up StudiesHumansItalyMaleMiddle AgedMyocardial InfarctionPatient CompliancePatient DischargeRecurrenceAdrenergic beta-Antagonistsadrenergic β‐antagonistsbias (epidemiology)medication adherencemyocardial infarctionsecondary prevention

Identifiers

PMID25567050
PMCPMC4330079

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.